HAE
Haemonetics Corporation
NYSE: HAE · HEALTHCARE · MEDICAL DEVICES
$52.67
-5.30% today
Updated 2026-05-06
Market cap
$2.75B
P/E ratio
16.33
P/S ratio
2.09x
EPS (TTM)
$3.63
Dividend yield
—
52W range
$47 – $87
Volume
0.7M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B5.5
Quality
C+7.0
Profitability
B+8.7
Valuation
A4/9
Piotroski F-Score
Moderate
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$84.60
+60.62%
12-Month target
$56.83
+7.90%
Intrinsic (DCF)
$102.84
Margin of safety
+44.09%
4 Strong Buy3 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $87.22M — positive
+ 44.09% below intrinsic value
Risks
- Altman Z 1.57 — distress zone
- Revenue declining -2.70% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $993.20M | $1.17B | $1.31B | $1.36B | $1.32B |
| Net income | $43.38M | $115.40M | $117.56M | $167.68M | $44.74M |
| EPS | — | — | — | — | $3.63 |
| Free cash flow | $75.75M | $162.87M | $115.45M | $142.45M | $87.22M |
| Profit margin | 4.37% | 9.87% | 8.98% | 12.32% | 13.30% |
Peer comparison
Smart narrative
Haemonetics Corporation trades at $52.67. representing a P/E of 16.33x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.57, it sits in the distress. TTM revenue stands at $1.32B. with profit margins at 13.30%. Our DCF model estimates intrinsic value at $102.84.
Frequently asked questions
What is Haemonetics Corporation's stock price?
Haemonetics Corporation (HAE) trades at $52.67.
Is Haemonetics Corporation overvalued?
Smart Value Score 64/100 (Grade C+, Hold). DCF value $102.84.
What is the price target of Haemonetics Corporation (HAE)?
The analyst target price is $84.60, representing +60.6% upside from the current price of $52.67.
What is the intrinsic value of Haemonetics Corporation (HAE)?
Based on our DCF model, intrinsic value is $102.84, a +44.1% margin of safety versus $52.67.
What is Haemonetics Corporation's revenue?
TTM revenue is $1.32B.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
1.57 — distress.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.09x
ROE19.30%
Beta0.36
50D MA$60.02
200D MA$63.54
Shares out0.05B
Float0.05B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—